長春高新(000661.SZ):子公司取得成都信立泰重組人促卵泡激素-CTP融合蛋白注射液相關權益
格隆匯 12 月 11日丨長春高新(000661.SZ)公佈,2020年12月11日,公司控股子公司長春金賽藥業有限責任公司(“金賽藥業”)與信立泰(成都)生物技術有限公司(“成都信立泰”)簽署合作協議,成都信立泰將其開發的處於I期臨牀試驗階段的在研品種“重組人促卵泡激素-CTP融合蛋白注射液”(“FSH-CTP”)在中國大陸地區的全部技術所有權和知識產權(包括與製造該重組人促卵泡激素-CTP融合蛋白注射液有關的實體物品,以及相關知識產權、非專利技術等研發成果的所有權,以及由標的轉讓產生的後續全部權利和經濟收益)轉移給金賽藥業。
“重組人促卵泡激素-CTP融合蛋白注射液”為7類生物類似物,開發適應症為輔助生殖中與GnRH拮抗劑聯合應用,促進女性多卵泡發育。該產品是一種長效的重組人促卵泡素,擬每週給藥一次,可提高患者便利性和依從性。目前尚處於I期臨牀試驗階段。
此協議涉及的技術轉讓費總金額為人民幣6068萬元。
此次合作的FSH-CTP注射液是成都信立泰開發的長效FSH,可以達到7天給藥1次。相對於目前國內市場上短效FSH的每天給藥1次,FSH-CTP可以提高患者的便利性和依從性,其已經獲得國家藥品監督管理局頒發的臨牀批件,目前正在I期臨牀試驗當中。
通過此次合作,能夠完善金賽藥業輔助生殖領域未來產品線,增加其在生殖領域的產品覆蓋,促進金賽藥業在輔助生殖領域的品牌建設,符合其未來發展戰略。從公司可持續發展角度看,本次就該產品達成的合作,有利於拓寬公司的業務結構,有助於完善戰略領域產品線佈局,提升公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.